RaDiCo-PID - Idiopathic Interstitial Pneumonia: From Infancy to Elderly
Responsable(s) :
Cottin Vincent , Inserm UMR754
Date de modification : 26/01/2024 | Version : 2 | ID : 73380
| Général | |
| Identification | |
| Nom détaillé | Idiopathic Interstitial Pneumonia: From Infancy to Elderly |
| Sigle ou acronyme | RaDiCo-PID |
| Numéro d'enregistrement (ID-RCB ou EUDRACT, CNIL, CPP, etc.) | CCTIRS n° 16.050Bis / CNIL Decision n° DR-2016-431 |
| Thématiques générales | |
| Domaine médical |
Pediatrics Pneumology Radiology and medical imaging Rare diseases |
| Etude en lien avec la Covid-19 |
No |
| Pathologie, précisions | Idiopathic Interstitial Pneumonia: Idiopathic Interstitial Pneumonia (IIP), known in French as “Pneumopathies Interstitielles Diffuses (PID)” and referred in the current protocol as IPP/PID, encompass a group of diffuse infiltrative lung diseases of unknown origin that affect the lung architecture and are characterized by a progressive and often irreversible remodeling of the lung. Clinical expression includes mainly dyspnea, restriction on pulmonary function testing, impaired haematosis and radiologic diffuse lung infiltration. In most situations, these diffuse lung disorders are chronic, with high morbidity and mortality due to the lack of curative therapy. |
| Déterminants de santé |
Climate Genetic Healthcare system and access to health care services Lifestyle and behavior Medicine Occupation Pollution Social and psychosocial factors |
| Responsable(s) scientifique(s) | |
| Nom du responsable | Cottin |
| Prénom | Vincent |
| Adresse |
Hôpital Louis Pradel, Hospices Civils de Lyon Service de pneumologie, 28 avenue Doyen Lepine, F-69677, Lyon France |
| Téléphone | +33 (0)4 27 85 77 00 |
| vincent.cottin@chu-lyon.fr | |
| Laboratoire | Inserm UMR754 |
| Organisme | French National Institute for Health and Medical Research (Inserm) |
| Collaborations | |
| Participation à des projets, des réseaux, des consortiums |
Yes |
| Précisions | Rare Pulmonary Diseases Healthcare Network RespiFil / European Reference Network ERN-LUNG |
| Financements | |
| Financements |
Mixed |
| Précisions | Funded by the French « Investissements d’Avenir » cohorts programme, Grant « ANR » 10-COHO-0003. This study is also supported by industrial funding within the framework of a public-private partnership. |
| Gouvernance de la base de données | |
| Organisation(s) responsable(s) ou promoteur | French National Institute for Health and Medical Research (Inserm) |
| Statut de l’organisation |
Secteur Public |
| Existence de comités scientifique ou de pilotage |
Yes |
| Labellisations et évaluations de la base de données | Security audit certification of the database |
| Contact(s) supplémentaire(s) | |
| Caractéristiques | |
| Type de base de données | |
| Type de base de données |
Morbidity registers |
| Base de données issues d'enquêtes, précisions |
Cohort study |
| Origine du recrutement des participants |
A selection of health institutions and services |
| Critère de sélection des participants |
Another treatment or procedure |
| Le recrutement dans la base de données s'effectue dans le cadre d'une étude interventionnelle |
No |
| Informations complémentaires concernant la constitution de l'échantillon |
The goal of the IIP/PID cohort is to include prevalent and incident IIP/PID cases diagnosed in paediatric patients and adult patients. For the prevalent cases and the retrospective nature of the data, a diagnosis validation will be required.
Paediatric patient population Pediatric IIP/PID patients include all patients with diffuse parenchymal diseases linked to rare conditions others than immune deficiencies, proliferative disorders, metabolic disorders, and drug toxicity. Since the first description of the RespiRare IIP/PID paediatric cases, almost 400 patients (prevalent cases) have been included in the database. Around 60-80 new IIP/PID cases (incident cases) are currently reported per year. However, this number is underestimated, and will most likely increase with the identification of more adapted diagnostic criteria. Adult patient population For IIP/PID patients with IPF (approximately two thirds of the IIP/PID adult patients): considering the relatively large number of patients mainly aged and with a very poor prognosis, only prospective data will be collected to maximize the longitudinal collection of data and allow a detailed and accurate description of disease evolution in this population. For IIP/PID patients without IPF but with diffuse parenchymal diseases linked to rare conditions others than immune deficiencies, proliferative disorders, metabolic disorders, and drug toxicity (approximately one third of the IIP/PID adult patients): IIP/PID, incident cases and prevalent cases (with retrospective data) will be included in the cohort. About 2000 adult IIP/PID patients are expected to be recruited during this study. |
| Objectif de la base de données | |
| Objectif principal |
Primary Objective
The main objective is to describe the phenotypic features of the paediatric and adult patients with IIP/PID, at diagnosis and during the follow-up. These data will be critical for the description of the natural history of the various forms of IIP/PID. Secondary Objectives The secondary objectives are to: • Identify gene factors involved in disease initiation and progression, • Investigate the extent to which environmental and co-morbidity factors may influence disease severity and outcome • Identify and validate biomarkers for disease diagnosis and progression Exploratory objectives • Production of improved strategies for patient recruitment and enrolment into clinical trials • Development of novel strategy for patient follow-up • Development of novel diagnostic approaches • Evaluation of effect on natural history of disease, and tolerance of therapy, in a large population in real life • Development of novel therapeutic approaches Information Technology Objectives • Develop and diffuse an electronic tool of data collection from various sources linked to a database integrating a system of management and follow-up of data-management allowing collection of data for IIP/PID paediatric and adult patients. • Include data generated by patients and, where relevant, their parents and/or carers. |
| Critères d'inclusion |
Patient with a diagnosis of IIP/PID
IIP/PID diagnosis is established on presenting history, clinical, radiological and functional and if available pathological findings. Inclusion criteria include: Clinical criteria: chronic respiratory insufficiency manifestations including dyspnea/tachypnea, cough, and cyanosis during exercise or at rest Radiological criteria: characteristic chest High-Resolution Computed Tomography (HRCT) abnormalities including widespread ground glass or alveolar attenuation, reticulation often associated with traction bronchiectasis, and honeycombing Functional criteria: pulmonary function test abnormalities reflecting a restrictive pattern and including: loss of lung volume, vital capacity (VC), total lung capacity (TLC); reduction in the diffusion capacity of the lung for carbon monoxide (DLCO), gas exchange abnormalities, and altered ventilatory response to exercise Patients (parents/guardians for paediatric/patients) having given an informed consent to participate in the protocol Patients affiliated to the “Regime National d’Assurance Maladie” Non-inclusion Criteria Patients with diffuse parenchymal lung diseases caused by drug toxicity, immunodeficiency, proliferative disorders including histiocytosis, and metabolic disorders Patients (parents/guardians for paediatric patient) not able to approve/understand the protocol |
| Type de population | |
| Age |
Newborns (birth to 28 days) Infant (28 days to 2 years) Early childhood (2 to 5 years) Childhood (6 to 13 years) Adolescence (13 to 18 years) Adulthood (19 to 24 years) Adulthood (25 to 44 years) Adulthood (45 to 64 years) Elderly (65 to 79 years) Great age (80 years and more) |
| Population concernée |
Sick population |
| Pathologie | J84 - Other interstitial pulmonary diseases |
| Sexe |
Male Woman |
| Champ géographique |
National |
| Détail du champ géographique | Complete national coverage through the network of rare pulmonary disease reference and ciompetence centers |
| Collecte | |
| Dates | |
| Année du premier recueil | 2017 |
| Année du dernier recueil | 2021 minimum |
| Taille de la base de données | |
| Taille de la base de données (en nombre d'individus) |
[1000-10 000[ individuals |
| Détail du nombre d'individus | 2550 |
| Données | |
| Activité de la base |
Current data collection |
| Type de données recueillies |
Clinical data Declarative data Paraclinical data Biological data |
| Données cliniques, précisions |
Direct physical measures Medical registration |
| Détail des données cliniques recueillies | The main variables collected include demographic aspects, family history, clinical examination results, environmental data, socio-professional details, patients' medical history, anatomopathological characteristics, biological, microbiological, and imaging tests. Both studies also involve bronchoscopic procedures, respiratory function measurements, disease progression monitoring, fertility data collection, genetic aspects, treatment records, quality of life questionnaires, and the inclusion of information on the Covid-19 episode. |
| Données déclaratives, précisions |
Paper self-questionnaire Internet self-questionnaire Face to face interview |
| Détail des données déclaratives recueillies | SF36 or SF10 + St George’s Hospital |
| Données biologiques, précisions | Record of biological results (hematology, biochemical, immunity, serology); Record of results for: bacteriology, virology, parasitology, mycology, bronchoscopy, bronchoalveolar lavage examination; Record of lung function tests, arterial blood gas and spirometry (If available sleep gas exchange and polysomnography); If available/performed, records of results for lung tissue examination, lung biopsy (surgical, transbronchial), lung explant; If available/performed, records of other organ function evaluation (including digestive and cardiac examinations) |
| Existence d’une biothèque |
Yes |
| Contenu de la biothèque |
Serum Fluids (saliva, urine, amniotic fluid, …) Tissues DNA Others |
| Détail des éléments conservés | plus broncho alveolar liquids |
| Paramètres de santé étudiés |
Health event/morbidity Health event/mortality Health care consumption and services Quality of life/health perception Others |
| Consommation de soins, précisions |
Hospitalization Medical/paramedical consultation Medicines consumption |
| Qualité de vie/santé perçue, précisions | SF36 or SF10 + St George’s Hospital |
| Modalités | |
| Mode de recueil des données | eCRF using REDCap; Cloud based, secure by design, web accessible platform. Certified Health Data Hosting resource |
| Nomenclatures employées | HPO, ICD10, Snomed CT, Orpha Codes and ORDO, Drug dictionary (DCIs) |
| Procédures qualité utilisées | Continuous data management; Data Management Plan and Data Validation Plan. Native controls and Query system |
| Suivi des participants |
Yes |
| Modalités de suivi des participants |
Monitoring by convocation of the participant Monitoring by contact with the referring doctor Monitoring by crossing with a medical-administrative database |
| Appariement avec des sources administratives |
No |
| Valorisation et accès | |
| Valorisation et accès | |
| Accès | |
| Existence d’un document qui répertorie les variables et les modalités de codage |
Yes |
| Charte d'accès aux données (convention de mise à disposition, format de données et délais de mise à disposition) | Access requests to RaDiCo-PID data (rough / structured), biocollections or to analytic reports will be examined by the scientific committee following submission of a Specific Research Project (SRP) synopsis, as defined in the Resource Access Charter. Must be sent to pid@radico.fr |
| Accès aux données agrégées |
Access on specific project only |
| Accès aux données individuelles |
Access on specific project only |
